Floatz logo

Defosbarasertib

Advanced Solid Tumours

AstraZenecaSmall moleculePhase 1Dormant
C
35/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
20/ 100
Competitive Position
89/ 100

Competitive context

30 Active assets in the Advanced Solid Tumours cohort.

Asset / SponsorPhaseRating
Ceralasertib
AstraZeneca
Phase 2BB
Cyclophosphamide
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Phase 2B
Pembrolizumab
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Phase 2B
Senaparib
Impact Therapeutics, Inc.
Phase 1/2B
Epirubicin
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Phase 2B

View all 50 →

Same molecule, other indications

Defosbarasertib is also rated in:

small cell lung carcinomaDormant
C
Indicative ·
39 / 100
View asset →
small cell lung carcinomaDormant
C
Indicative ·
39 / 100
View asset →
acute myeloid leukemiaDormant
C
Indicative ·
33 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →